Loading stock…

MiniMed Group, Inc. (MMED) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

MiniMed Group, Inc.

MMEDMarket cap $5.38BPrice $19.1

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Develops and manufactures medical devices for chronic disease management, focusing on precision drug-delivery systems. Its technology helps patients manage conditions like diabetes with less hassle, competing in a space where reliability can mean the difference between life and death.

In Bastion Portfolios?

52W Return+27%

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+11%6

Rev CAGR (3y)+10%7

Rev CAGR (5y)+10%8

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2-3%3

EPS Growth Y+3+175%10

Quality

Margins

EBIT Margin4%2

Net Income Margin-10%1

Free Cash Flow Margin-10%2

Debt

Net Debt/EBITDA-0.510

Efficiency

ROE-9%1

ROAna–

Earnings Stability88

GEAR+WEAK19

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)332

P/E Ratio (Forward 3y)117

P/BV1.58

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd223

Yield

Free Cash Flow Yield-5.9%1

Dividend Yieldna–

Momentum

Short term

1 month return-18%1

3 month return+27%10

YTD return+3%5

Mid term

Price vs 52wHigh78%5

1 year return+3%5

Long term

3 year return+3%3

5 year return+3%4

Risk Shield

Price Risk

Betana–

Volatility56%2

Free Cash Flow

Free Cash Flow Margin-10%2

Free Cash Flow Yield-5.9%1

Quality

ROCE7%4

Earnings Stability88

Net Debt/EBITDA-0.510

02Growth

Is it actually growing, and how fast?

MMEDMiniMed Group

Revenue FY26$3.1B

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+10%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E0%5

EPS growth, FY28E-3%3

EPS growth, FY29E+175%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.8/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return+27%10

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return+3%5

3-year return+3%3

5-year return+3%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+27%).

WATCH

It's up 3% over the past year, but 22% below its 52-week high. That is right in line with the market.

Returns sit at the market level so far this year (+3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+3.4% over three years and +3.4% over five), behind 60% of the market.

The stock is underperforming over the past month (-18%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on MiniMed Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MMEDMiniMed Group

Revenue FY26$3.1B

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+10%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E0%5

EPS growth, FY28E-3%3

EPS growth, FY29E+175%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.8/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return+27%10

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return+3%5

3-year return+3%3

5-year return+3%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+27%).

WATCH

It's up 3% over the past year, but 22% below its 52-week high. That is right in line with the market.

Returns sit at the market level so far this year (+3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+3.4% over three years and +3.4% over five), behind 60% of the market.

The stock is underperforming over the past month (-18%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on MiniMed Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community